TWI879228B - 取代的哌衍生物的晶型及其製備方法、藥物組合物和製藥用途 - Google Patents

取代的哌衍生物的晶型及其製備方法、藥物組合物和製藥用途 Download PDF

Info

Publication number
TWI879228B
TWI879228B TW112143895A TW112143895A TWI879228B TW I879228 B TWI879228 B TW I879228B TW 112143895 A TW112143895 A TW 112143895A TW 112143895 A TW112143895 A TW 112143895A TW I879228 B TWI879228 B TW I879228B
Authority
TW
Taiwan
Prior art keywords
crystal
solvent
crystal form
ray powder
powder diffraction
Prior art date
Application number
TW112143895A
Other languages
English (en)
Chinese (zh)
Other versions
TW202426452A (zh
Inventor
劉兆軍
楚洪柱
朱鈺沁
曹鑫
魏用剛
孫毅
Original Assignee
康百達（四川）生物醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 康百達（四川）生物醫藥科技有限公司 filed Critical 康百達（四川）生物醫藥科技有限公司
Publication of TW202426452A publication Critical patent/TW202426452A/zh
Application granted granted Critical
Publication of TWI879228B publication Critical patent/TWI879228B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW112143895A 2022-11-14 2023-11-14 取代的哌衍生物的晶型及其製備方法、藥物組合物和製藥用途 TWI879228B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022114177213 2022-11-14
CN202211417721 2022-11-14

Publications (2)

Publication Number Publication Date
TW202426452A TW202426452A (zh) 2024-07-01
TWI879228B true TWI879228B (zh) 2025-04-01

Family

ID=90997576

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112143895A TWI879228B (zh) 2022-11-14 2023-11-14 取代的哌衍生物的晶型及其製備方法、藥物組合物和製藥用途

Country Status (9)

Country Link
US (1) US20250270223A1 (https=)
EP (1) EP4620958A1 (https=)
JP (1) JP2025536416A (https=)
KR (1) KR20250086779A (https=)
CN (1) CN118027039A (https=)
AU (1) AU2023381502A1 (https=)
MX (1) MX2025005591A (https=)
TW (1) TWI879228B (https=)
WO (1) WO2024104354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508597A (zh) * 2023-08-17 2025-03-01 大陸商康百達（四川）生物醫藥科技有限公司 一種呱嗪衍生物的藥物製劑、其製備方法及其用途
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112424188A (zh) * 2018-04-30 2021-02-26 里邦医疗公司 作为parp7抑制剂的哒嗪酮
WO2022242750A1 (zh) * 2021-05-21 2022-11-24 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112745312B (zh) * 2019-10-30 2022-08-30 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达（四川）生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112424188A (zh) * 2018-04-30 2021-02-26 里邦医疗公司 作为parp7抑制剂的哒嗪酮
WO2022242750A1 (zh) * 2021-05-21 2022-11-24 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用

Also Published As

Publication number Publication date
CN118027039A (zh) 2024-05-14
TW202426452A (zh) 2024-07-01
WO2024104354A1 (zh) 2024-05-23
MX2025005591A (es) 2025-06-02
AU2023381502A1 (en) 2025-05-15
EP4620958A1 (en) 2025-09-24
US20250270223A1 (en) 2025-08-28
JP2025536416A (ja) 2025-11-05
KR20250086779A (ko) 2025-06-13

Similar Documents

Publication Publication Date Title
TWI527800B (zh) 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
TWI879228B (zh) 取代的哌衍生物的晶型及其製備方法、藥物組合物和製藥用途
JP3763414B2 (ja) Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
JP2006503010A (ja) 数種の新規なイミダゾピリジンおよびその使用
KR20100072266A (ko) 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제
JP2020504747A (ja) ベンズイミダゾール誘導体、調製方法およびそれらの使用
CN106661025B (zh) 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法
CN114853672B (zh) 作为CDKs抑制剂的他克林衍生物及其应用
JP2023504866A (ja) 大環構造を有するフッ素含有複素環誘導体およびその用途
WO2018192536A1 (zh) 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用
JP2022517085A (ja) ハロゲン化アリルアミン系化合物及びその適用
EP3590941A1 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
KR20220020951A (ko) Cdk 키나제 억제제
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
JP2021529175A (ja) Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用
WO2010064737A1 (ja) 複素環化合物およびその用途
CN116003406B (zh) 杂芳环氮氧化合物及其制备方法和应用
TWI525091B (zh) 吡咯並喹啉基－吡咯啶－２，５－二酮組成物類及製備和使用彼等之方法
KR20220143666A (ko) 다환 역형성 림프종 키나아제 억제제의 결정형
HK40104801A (zh) 一种取代的哌嗪衍生物的晶体及其制备方法
TWI919884B (zh) 一種嘧啶并氮雜環類化合物的晶型及其製備方法及應用
US9073921B2 (en) Salt forms of bicyclic heterocyclic derivatives
TW200301120A (en) 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino [4,5-b] indole-1-carboxamide derivatives, their preparation and their application in therapeutics
TW202547508A (zh) 一種嘧啶并氮雜環類化合物的晶型及其製備方法及應用
EP4036086A1 (en) Heterocyclic derivative and use thereof